Abstract 337P
Background
To determine the percentage of breast cancers detectable by fused diffusion-weighted imaging (DWI) using unenhanced magnetic resonance imaging (MRI) and abbreviated post-contrast-enhanced MRI.
Methods
Between October 2016 and October 2017, 194 consecutive women (mean age, 54.2 years; age range, 28-82 years) with newly diagnosed unilateral breast cancer who underwent preoperative 3.0 T breast MRI with DWI were evaluated. Both fused DWI and abbreviated MRI images were independently reviewed by two radiologists for the detection of index cancer (which showed the most suspicious findings in both breasts), location, lesion conspicuity, lesion type, and lesion size. Moreover, the relationship between cancer detection and histopathological results of surgical specimens were evaluated.
Results
Index cancer detection rates were comparable between fused DWI and abbreviated MRI (radiologist 1: 174/194 [89.7%] vs. 184/194 [94.8%], respectively, P = 0.057; radiologist 2: 174/194 [89.7%] vs. 183/194 [94.3%], respectively, P = 0.092). In both radiologists, abbreviated MRI showed a significantly higher lesion conspicuity than fused DWI (radiologist 1: 9.37 ± 2.24 vs. 8.78 ± 3.03, P < 0.001; radiologist 2: 9.16 ± 2.32 vs. 8.39 ± 2.93, P < 0.001). The κ value for the interobserver agreement of index cancer detection was 0.67 on fused DWI and 0.85 on abbreviated MRI. For lesion conspicuity, the intraclass correlation coefficients were 0.72 and 0.82 on fused DWI and abbreviated MRI, respectively. Among the histopathological factors, tumor invasiveness was associated with cancer detection on both fused DWI (P = 0.011) and abbreviated MRI (P = 0.004, radiologist 1), lymphovascular invasion was associated with cancer detection on abbreviated MRI (P = 0.032, radiologist 1), and necrosis was associated with cancer detection on fused DWI (P = 0.031, radiologist 2).
Conclusions
Index cancer detection was comparable between fused DWI and abbreviated MRI, although abbreviated MRI showed a significantly better lesion conspicuity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
252P - Adjuvant chemotherapy in T1a/bN0 breast cancer patients with high oncotype DX recurrence scores (RS>25)
Presenter: Daniela Katz
Session: Poster session 02
253P - Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK
Presenter: Vasileios Angelis
Session: Poster session 02
254P - Effects of delaying adjuvant chemotherapy initiation on clinical outcomes in early triple-negative breast cancer patients
Presenter: Maria Eleni Hatzipanagiotou
Session: Poster session 02
255P - Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 02
256P - Evolution and risk stratification of adjuvant treatment strategies for early breast cancer: A Chinese perspective based on a national cancer database
Presenter: Ying Fan
Session: Poster session 02
257P - The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients: A real-world study
Presenter: Bo Lan
Session: Poster session 02
258P - Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
Presenter: Ricardo Brugés Maya
Session: Poster session 02
259P - Adjuvant doxorubicin-cyclophosphamide in early-stage breast cancer provides long-term cardiac safety
Presenter: Thiti Susiriwatananont
Session: Poster session 02
260P - Oncology efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
Presenter: Hee Jun Choi
Session: Poster session 02
261P - Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC patients
Presenter: Bernardo Rapoport
Session: Poster session 02